Omlonti is a relatively selective EP2 receptor agonist designed to increase aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways.
Most patients with CKD and apparent treatment-resistant hypertension had uncontrolled resistant hypertension or refractory hypertension.
The approvals were based on data from the LIBRETTO-001 trial.
Drugs in the Pipeline
The sNDA submission is based on data from a phase 2 trial, which included 117 patients with HER2-positive unresectable or metastatic colorectal cancer following previous standard of care therapies.
Xenpozyme is a hydrolytic lysosomal sphingomyelin-specific enzyme replacement therapy designed to replace deficient or defective ASM.